GLP-1 RAs showed a trend toward improvements in renal damage markers and albuminuria indicators, and toward reduced risks of renal failure and composite renal outcomes across various populations
FDA Schedules July 2026 PCAC Review of BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon, DSIP The FDA Pharmacy Compounding Advisory Committee will review BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon and DSIP for the 503A bulks list in July 2026
Excellent service and guidance through the process
Moreover, GLP-1s are no longer just for diabetes
To be clear, the evidence linking GLP-1 agonists to gastroparesis and pancreatitis is suggestive, not definitive
By improving the skins internal health, you enhance the longevity and quality of your external cosmetic results